Physician profile
Nyla Hashim
NPI 1659914851
$1,324.16
in general payments reported to CMS, 2019-2025
14 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $31.98 · 2023: $616 · 2024: $676.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,237 · Education: $54.95.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,237.23 |
| Education | $54.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $350.53 | 2023-2024 | Fasenra, Tezspire, Airsupra |
| Takeda Pharmaceuticals U.S.A., INC. | $270.96 | 2023-2024 | Hyqvia, Cuvitru |
| Glaxosmithkline, LLC. | $177.24 | 2021-2024 | Nucala, Arexvy, Trelegy Ellipta |
| Incyte Corporation | $134.68 | 2023-2024 | Opzelura |
| Regeneron Healthcare Solutions, INC. | $82.26 | 2023-2024 | Dupixent |
| Genzyme Corporation | $76.86 | 2023-2024 | |
| Genentech USA, INC. | $70.24 | 2023-2024 | Xolair |
| Sanofi-Aventis U.S. LLC | $54.95 | 2023 | |
| Grifols USA, LLC | $24.16 | 2024 | Xembify |
| Biocryst US Sales Co., LLC | $20.31 | 2023 | Orladeyo |
| Abbvie INC. | $16.06 | 2024 | |
| Merck Sharp & Dohme LLC | $15.74 | 2023 | |
| Blueprint Medicines Corporation | $15.51 | 2024 | Ayvakit |
| Csl Behring | $14.66 | 2023 | Privigen, Hizentra |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nyla Hashim listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.